Beat AML® Study Provides New Data on 14-Day vs. 28-Day Venetoclax-Azacitidine Treatment in AML

Clinicians often reduce the duration of venetoclax because of side effects, but study finds 14-day schedule fell short in older patients with newly diagnosed AML WASHINGTON, July 30, 2026 /PRNewswire/ -- New study results from Blood Cancer United's Beat AML® Master Clinical Trial,...